{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.1014",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2022-07-13T01:02:20.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Clinical Architecture"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2023-06-21"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2022-07-13"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.1014",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.1014"
    }
  ],
  "version" : "20220713",
  "name" : "CasirivimabImdevimabAdministration",
  "title" : "Casirivimab / Imdevimab Administration",
  "status" : "active",
  "experimental" : false,
  "date" : "2023-06-21T18:16:37-04:00",
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to intravenous or subcutaneous administration of casirivimab / imdevimab.),(Data Element Scope: ),(Inclusion Criteria: Includes terms related to intravenous or subcutaneous administration of casirivimab / imdevimab.),(Exclusion Criteria: )",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "concept" : [
          {
            "code" : "M0240",
            "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses"
          },
          {
            "code" : "M0241",
            "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses"
          },
          {
            "code" : "M0243",
            "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring"
          },
          {
            "code" : "M0244",
            "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency"
          },
          {
            "code" : "Q0240",
            "display" : "Injection, casirivimab and imdevimab, 600 mg"
          },
          {
            "code" : "Q0243",
            "display" : "Injection, casirivimab and imdevimab, 2400 mg"
          },
          {
            "code" : "Q0244",
            "display" : "Injection, casirivimab and imdevimab, 1200 mg"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:af3f9064-a68c-4a0e-a318-afed3a66a32e",
    "timestamp" : "2023-11-26T20:09:39-05:00",
    "total" : 7,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "M0240",
        "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "M0241",
        "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "M0243",
        "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "M0244",
        "display" : "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "Q0240",
        "display" : "Injection, casirivimab and imdevimab, 600 mg"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "Q0243",
        "display" : "Injection, casirivimab and imdevimab, 2400 mg"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "Q0244",
        "display" : "Injection, casirivimab and imdevimab, 1200 mg"
      }
    ]
  }
}
